| P50 | author | Christian Gluud | Q26265142 |
| | Jørn Wetterslev | Q28037207 |
| | Maria Skoog | Q28320216 |
| | Asbjørn Hróbjartsson | Q30004128 |
| | Berit Grevstad | Q114426373 |
| P2860 | cites work | Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis | Q24289436 |
| | Bias in meta-analysis detected by a simple, graphical test | Q24685585 |
| | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860537 |
| | Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 |
| | Meta-analysis in clinical trials | Q27860779 |
| | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| | Systematic reviews in health care: Assessing the quality of controlled clinical trials | Q29618659 |
| | Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses | Q29619185 |
| | Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? | Q29619328 |
| | Meta-analyses involving cross-over trials: methodological issues | Q29620304 |
| | Estimating required information size by quantifying diversity in random-effects model meta-analyses. | Q33521365 |
| | Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease | Q33646625 |
| | Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies | Q33776566 |
| | H pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease. | Q33866718 |
| | Infections, inflammation, and the risk of coronary heart disease | Q33887538 |
| | Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses | Q33910496 |
| | The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study | Q34058272 |
| | Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial | Q34248742 |
| | Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials | Q34422834 |
| | Relationship between Chlamydia pneumoniae infection, inflammatory markers, and coronary heart diseases. | Q34503313 |
| | Virus-induced atherosclerosis | Q36341613 |
| | Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses | Q37138228 |
| | Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis | Q37346172 |
| | Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis | Q37872578 |
| | Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial | Q37873906 |
| | Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study | Q37878753 |
| | Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamyd | Q37878769 |
| | Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease | Q37878785 |
| | Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction | Q37878896 |
| | The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production | Q37881386 |
| | Chronic infections and coronary heart disease: is there a link? | Q37882245 |
| | Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction | Q37882420 |
| | Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group | Q37883953 |
| | Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease | Q37884972 |
| | Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors | Q37886448 |
| | Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease | Q37887196 |
| | Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators | Q37890128 |
| | Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain | Q37890285 |
| | Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease | Q37891247 |
| | Association of Prior Infection With Chlamydia pneumoniae and Angiographically Demonstrated Coronary Artery Disease | Q37892814 |
| | Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease | Q37894988 |
| | Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction | Q37896424 |
| | Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction | Q37899465 |
| | Relation of C reactive protein to cardiovascular risk factors. H pylori and C pneumoniae infections may account for most acute coronary syndromes | Q43189191 |
| | Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk In Communities (ARIC) Study Investigators. | Q50866437 |
| | Methods for combining randomized clinical trials: strengths and limitations. | Q52599212 |
| | Cytomegalovirus infection and coronary heart disease risk: a meta-analysis. | Q53095337 |
| | Macrolide antibiotics as antiinflammatory agents: roxithromycin in an unexpected role | Q70676527 |
| P921 | main subject | antibiotic | Q12187 |
| | coronary artery disease | Q844935 |
| P577 | publication date | 2013-02-28 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Antibiotics for secondary prevention of coronary heart disease | |